Search results for "intravenous"

showing 10 items of 390 documents

Ver�nderungen der Wasser- und Salzausscheidung sowie der Nierenstruktur w�hrend des 2.?10. Tages nach einmaliger intraven�ser Zufuhr von Chlormerodrin

1959

Pharmacologychemistry.chemical_classificationIntravenous dosebusiness.industryPharmacology toxicologyKidney pharmacologySalt (chemistry)Kidney structureGeneral MedicinePharmacologyExcretionchemistryWater metabolismMedicinebusinessNaunyn-Schmiedeberg's Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Successful “Salvage” Therapy of Intravenous Cyclophosphamide for Refractory Polymyositis in an Elderly Patient: Case Report

2006

Dermatomyositis and polymyositis may affect children and adults and are now widely recognized as major causes of disability which, thanks to the introduction of immunosuppressive drugs, is often treatable, at least to some extent. Few data exist regarding polymyositis in elderly patients. We describe a case of refractory life-threatening polymyositis in an elderly patient, successfully treated with intravenous cyclophosphamide.

Pharmacologymedicine.medical_specialtybusiness.industryImmunologySalvage therapyDermatomyositismedicine.diseasePolymyositisSurgery03 medical and health sciences0302 clinical medicineIntravenous cyclophosphamideRefractory030220 oncology & carcinogenesismedicineImmunology and AllergyElderly patientbusiness030215 immunologyInternational Journal of Immunopathology and Pharmacology
researchProduct

Guillain-Barré Syndrome

2022

Background: Guillain–Barré syndrome is a rare disorder in which our body’s immune system attacks nerves determining weakness and tingling of extremities as first symptoms. It can also be associated to respiratory failure and require mechanical ventilation during hospitalization (up to 30% of patients). Nowadays patient’s hyper-reactive immune responses benefits from immunotherapies such as intravenous immunoglobulin (IVIg), therapeutic plasma exchange (TPE) and new biological drugs. Case Report: We report our experience with the case of a 64-year-old woman who presented a symmetric progressive flaccid paralysis after a week of mild cold symptoms. The respiratory and neurological symptoms wo…

Plasma exchangeAcute inflammatory demyelinating polyneuropathyGeneral MedicineGuillain-Barré syndromeIntravenous immunoglobulinAnnals of Case Reports
researchProduct

A Machine Learning Model to Predict Intravenous Immunoglobulin-Resistant Kawasaki Disease Patients: A Retrospective Study Based on the Chongqing Popu…

2021

Objective: We explored the risk factors for intravenous immunoglobulin (IVIG) resistance in children with Kawasaki disease (KD) and constructed a prediction model based on machine learning algorithms.Methods: A retrospective study including 1,398 KD patients hospitalized in 7 affiliated hospitals of Chongqing Medical University from January 2015 to August 2020 was conducted. All patients were divided into IVIG-responsive and IVIG-resistant groups, which were randomly divided into training and validation sets. The independent risk factors were determined using logistic regression analysis. Logistic regression nomograms, support vector machine (SVM), XGBoost and LightGBM prediction models wer…

PopulationMachine learningcomputer.software_genreLogistic regressionPediatricsProcalcitoninRJ1-570Medicinerisk factorseducationOriginal Researcheducation.field_of_studyKawasaki diseasebusiness.industryRetrospective cohort studyNomogrammedicine.diseaseSupport vector machineprediction modelmachine learningPediatrics Perinatology and Child HealthKawasaki diseaseArtificial intelligencebusinesscomputerintravenous immunoglobulin resistancePredictive modellingFrontiers in Pediatrics
researchProduct

Intravenous gammaglobulin treatment in chronic progressive multiple sclerosis

1998

Progressive multiple sclerosismedicine.medical_specialtyPediatricsNeurologyNeuroscience (all)business.industryGeneral NeuroscienceMultiple sclerosisIntravenous gammaglobulinDermatologyGeneral Medicinemedicine.diseasePsychiatry and Mental healthmedicineChronic progressive multiple sclerosisSettore MED/26 - NeurologiaNeurosurgeryNeurology (clinical)businessNeuroradiology
researchProduct

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

2020

Background There is no proven specific pharmacological treatment for patients with the acute respiratory distress syndrome (ARDS). The efficacy of corticosteroids in ARDS remains controversial. We aimed to assess the effects of dexamethasone in ARDS, which might change pulmonary and systemic inflammation and result in a decrease in duration of mechanical ventilation and mortality. Methods We did a multicentre, randomised controlled trial in a network of 17 intensive care units (ICUs) in teaching hospitals across Spain in patients with established moderate-to-severe ARDS (defined by a ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen of 200 mm Hg or less assesse…

Pulmonary and Respiratory MedicineAdultMaleARDSmedicine.medical_treatmentSeverity of Illness IndexDexamethasonelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawFraction of inspired oxygenIntensive careSeverity of illnessmedicineData monitoring committeeHumans030212 general & internal medicineGlucocorticoidsDexamethasoneAgedMechanical ventilationRespiratory Distress Syndromebusiness.industryMiddle Agedmedicine.diseaseRespiration ArtificialIntensive Care UnitsTreatment Outcome030228 respiratory systemAnesthesiaAdministration IntravenousFemalebusinessmedicine.drug
researchProduct

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): A multicentre phase II clinical trial

2001

Abstract A phase II study in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) was carried out to evaluate the clinical activity and toxicity of the chemotherapeutic combination of gemcitabine+vinorelbine (GEM/VNR). Forty-five patients (40 male, 5 female) with a median age of 67 years (range 37–73) and a median ECOG performance status of 1 (range 0–2) were enrolled into the trial. Twenty patients had stage IIIB (two positive supraclavicular nodes and 20 cytologically positive pleural effusion), and 25 had stage IV NSCLC. GEM 1000 mg/m 2 diluted in 250 cc 3 of normal saline was administered iv on days 1, 8, and 15, while VNR was given 30 mg/m 2 on days 1 and 8 every 4 weeks. The…

Pulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaPleural effusionmedicine.drug_classnon-small cell lung cancer (NSCLC)Phases of clinical researchNeutropeniaVinorelbineVinblastineGastroenterologyAntimetaboliteDeoxycytidineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousAgedbusiness.industryVinorelbineMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabineGemcitabineSurgeryRegimenTreatment OutcomeOncologyInjections IntravenousFemalebusinessmedicine.drug
researchProduct

Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized s…

2002

Abstract Purpose: To compare a regimen of vinorelbine and cisplatin (VC) to the combination of mitomycin, vindesine, and cisplatin (MVP) in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC). The main endpoits were analysis of objective response rates, toxicity, time to progression, and overall survival. Patients and methods: 247 eligible patients were randomized to receive (a) vinorelbine 25 mg/m 2 intravenous bolus on days 1and 8 plus cisplatin 100 mg/m 2 on day 1 every 4 weeks, or (b) mitomycin c 8 mg/m 2 i.v. on day 1, vindesine 3 mg/m 2 i.v. on days 1, 8, 15 and 22, plus cisplatin 100 mg/m 2 on day 1 every 4 weeks. In subsequent cycles vindesine was given every oth…

Pulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsVindesinemedicine.medical_treatmentMitomycinVinorelbineVinblastineGastroenterologyDisease-Free SurvivalInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesInfusions IntravenousAgedNeoplasm StagingCisplatinChemotherapyPerformance statusDose-Response Relationship Drugbusiness.industryMitomycin CVinorelbineMiddle Agedmedicine.diseaseSurgerySurvival RateRegimenTreatment OutcomeOncologyDisease ProgressionVindesineFemaleCisplatinbusinessProgressive diseasemedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.

2019

Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma. However, while OCS are effective at treating acute exacerbations, there is only empirical evidence regarding the efficacy of OCS at reducing the rate of exacerbations. Evidence, although scarce, is suggestive of high exacerbation rates in severe asthma patients even when receiving maintenance treatment with OCS. In addition, use of OCS is associated with undesirable effects. Despite all this, physicians have continued to use OCS for managing severe asthma and acute exacerbation due to the lack of availability of effective…

Pulmonary and Respiratory MedicineMaleAllergymedicine.medical_specialtyExacerbationInjections SubcutaneousAdministration OralOmalizumabOmalizumabAntibodies Monoclonal HumanizedSeverity of Illness Indexchemistry.chemical_compoundReslizumabAdrenal Cortex HormonesInternal medicinemedicineHumansAnti-Asthmatic AgentsAsthmaBiological Productsbusiness.industryInterleukin-4 Receptor alpha SubunitImmunoglobulin Emedicine.diseaseBenralizumabReceptors Interleukin-5DupilumabAsthmachemistryAdministration IntravenousFemaleInterleukin-5businessMepolizumabmedicine.drug
researchProduct

Particulate Matter Contamination of Intravenous Antibiotics Aggravates Loss of Functional Capillary Density in Postischemic Striated Muscle

2002

Through the increased use of less expensive and counterfeit medicines, the contamination of parenteral fluids and drugs by particulate matter poses an increasing health hazard worldwide. However, the mechanism of action of such contamination has never been conclusively demonstrated. We have systemically injected the particles contained in three different 1-g preparations of the antibiotic cefotaxime into hamsters and visualized the functional capillary density in striated skin muscle, using intravital fluorescence microscopy. Injection of particles from either of the three preparations did not affect capillary perfusion in normal muscle (n = 3 hamsters, each). However, injection of particle…

Pulmonary and Respiratory MedicineMuscle tissuePathologymedicine.medical_specialtyIschemiaCefotaximeCritical Care and Intensive Care MedicineMicrocirculationSepsisCricetinaemedicineAnimalsHumansSingle-Blind MethodParticle SizeMuscle SkeletalRespiratory distressbusiness.industryMicrocirculationmedicine.diseaseMicrospheresCapillariesCephalosporinsmedicine.anatomical_structureReperfusion InjuryInjections IntravenousToxicityDrug ContaminationbusinessPerfusionReperfusion injuryAmerican Journal of Respiratory and Critical Care Medicine
researchProduct